Clinical Efficacy of Cerebrolysin and Cerebrolysin plus Nootropics in the Treatment of Patients with Acute Ischemic Stroke in Vietnam.

Tran L, Alvarez XA, Le HA, Nguyen DA, Le T, Nguyen N, Nguyen T, Nguyen T, Vo T, Tran T, Duong C, Nguyen H and 5 more

Show all authors

Nguyen S, Nguyen H, Le T, Nguyen M, Nguyen T

CNS & neurological disorders drug targets1 Jan 2022Cited by 4 (Europe PMC)

PMID34414874DOI10.2174/1871527320666210820091655PepBankPUB-34414874

Publisher page PubMedAsk about this study

Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

10 results from studies that gave the peptide. 10 results from people.

01HumanObservational studyEfficacy outcome
In AIS patients, Cerebrolysin was linked to improved mRS scores compared with other nootropics.
In plain wordsIn stroke patients, Cerebrolysin was linked to better disability scores compared with other nootropics.
Peptide
Cerebrolysin
Outcome
DecreasemRS score
Study
n: not reported in source
Comparator
Other nootropics
Analysis
Primary
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
10 ml · i.v.As given in this study (human).
Measurements
p value for mRS scores
< 0.001
Cerebrolysin versus other nootropics
Source sentences
Summary
Compared with other nootropics, both Cerebrolysin and combined therapy induced significant improvements (p<0.001) in: Functional recovery (mRS scores)
1 context sentence(design, population, supporting numbers)
Summary · context
This non-interventional, controlled, open-label, prospective and multicenter study included 398 AIS patients (234 males) treated with Cerebrolysin (n=190; 20 i.v. infusions of 10 ml), other nootropics (comparator group; n=86), or a combination of both (n=122).
Report a problemFND-3441487401
02HumanObservational studyEfficacy outcome
In AIS patients, Cerebrolysin plus nootropics was linked to improved mRS scores compared with nootropics alone.
In plain wordsIn stroke patients, Cerebrolysin plus nootropics was linked to better disability scores compared with nootropics alone.
Peptide
Cerebrolysin
Outcome
DecreaseCombination mRS score
Study
n: not reported in source
Comparator
Other nootropics
Analysis
Primary
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated
Measurements
p value for mRS scores
< 0.001
Cerebrolysin plus nootropics versus other nootropics
Source sentences
Summary
Compared with other nootropics, both Cerebrolysin and combined therapy induced significant improvements (p<0.001) in: Functional recovery (mRS scores)
1 context sentence(design, population, supporting numbers)
Summary · context
This non-interventional, controlled, open-label, prospective and multicenter study included 398 AIS patients (234 males) treated with Cerebrolysin (n=190; 20 i.v. infusions of 10 ml), other nootropics (comparator group; n=86), or a combination of both (n=122).
Report a problemFND-3441487406
03HumanObservational studyEfficacy outcome
In AIS patients, well-recovered proportions were 81.6% with Cerebrolysin versus 43.0% with other nootropics.
In plain wordsIn stroke patients, recovery was more frequent with Cerebrolysin than other nootropics.
Peptide
Cerebrolysin
Outcome
IncreasemRS 0-2 responders
Study
n: not reported in source
Comparator
Other nootropics
Analysis
Secondary
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
10 ml · i.v.As given in this study (human).
Measurements
Well-recovered patients (mRS 0-2)
81.6%
Cerebrolysin
Well-recovered patients (mRS 0-2)
43%
other nootropics (comparator)
p value for well-recovered patients (mRS 0-2)
< 0.001
Cerebrolysin versus other nootropics
Source sentences
Summary
percentage of well-recovered patients (Cerebrolysin: 81.6%; combination: 93.4%; comparator: 43.0%)
Summary
Compared with other nootropics, both Cerebrolysin and combined therapy induced significant improvements (p<0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
This non-interventional, controlled, open-label, prospective and multicenter study included 398 AIS patients (234 males) treated with Cerebrolysin (n=190; 20 i.v. infusions of 10 ml), other nootropics (comparator group; n=86), or a combination of both (n=122).
Report a problemFND-3441487402
04HumanObservational studyEfficacy outcome
In AIS patients, Cerebrolysin was linked to improved NIHSS change compared with other nootropics.
In plain wordsIn stroke patients, Cerebrolysin was linked to better neurological scores compared with other nootropics.
Peptide
Cerebrolysin
Outcome
DecreaseNIHSS change
Study
n: not reported in source
Comparator
Other nootropics
Analysis
Secondary
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
10 ml · i.v.As given in this study (human).
Measurements
p value for study-period NIHSS change
< 0.001
Cerebrolysin versus other nootropics
Source sentences
Summary
Compared with other nootropics, both Cerebrolysin and combined therapy induced significant improvements (p<0.001)
2 context sentences(design, population, supporting numbers)
Summary · context
neurological recovery (study- period NIHSS change)
Summary · context
This non-interventional, controlled, open-label, prospective and multicenter study included 398 AIS patients (234 males) treated with Cerebrolysin (n=190; 20 i.v. infusions of 10 ml), other nootropics (comparator group; n=86), or a combination of both (n=122).
Report a problemFND-3441487403
05HumanObservational studyEfficacy outcome
In AIS patients, good NIHSS response occurred in 77.5% with Cerebrolysin versus 47.6% with other nootropics.
In plain wordsIn stroke patients, neurological response was more frequent with Cerebrolysin than other nootropics.
Peptide
Cerebrolysin
Outcome
IncreaseGood NIHSS responders
Study
n: not reported in source
Comparator
Other nootropics
Analysis
Secondary
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
10 ml · i.v.As given in this study (human).
Measurements
Good NIHSS responders
77.5%
Cerebrolysin
Good NIHSS responders
47.6%
other nootropics (comparator)
p value for good NIHSS responders
< 0.001
Cerebrolysin versus other nootropics
Source sentences
Summary
proportion of good NIHSS responders (Cerebrolysin: 77.5%; combination: 92.5%; comparator: 47.6%)
Summary
Compared with other nootropics, both Cerebrolysin and combined therapy induced significant improvements (p<0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
This non-interventional, controlled, open-label, prospective and multicenter study included 398 AIS patients (234 males) treated with Cerebrolysin (n=190; 20 i.v. infusions of 10 ml), other nootropics (comparator group; n=86), or a combination of both (n=122).
Report a problemFND-3441487404
06HumanObservational studyEfficacy outcome
In AIS patients, MoCA scores were higher with Cerebrolysin than other nootropics.
In plain wordsIn stroke patients, thinking scores were higher with Cerebrolysin than other nootropics.
Peptide
Cerebrolysin
Outcome
IncreaseMoCA score
Study
n: not reported in source
Comparator
Other nootropics
Analysis
Secondary
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
10 ml · i.v.As given in this study (human).
Measurements
MoCA score (mean)
23.3 points
Cerebrolysin
MoCA score (mean)
15.9 points
other nootropics (comparator)
p value for MoCA scores
< 0.001
Cerebrolysin versus other nootropics
MoCA score reported ± uncertainty (type unspecified)
4.8 points
Cerebrolysin at day 90
MoCA score reported ± uncertainty (type unspecified)
7.7 points
other nootropics (comparator) at day 90
Source sentences
Summary
and MoCA scores (Cerebrolysin: 23.3±4.8; combination: 23.7±4.1; comparator: 15.9±7.7).
Summary
Compared with other nootropics, both Cerebrolysin and combined therapy induced significant improvements (p<0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
This non-interventional, controlled, open-label, prospective and multicenter study included 398 AIS patients (234 males) treated with Cerebrolysin (n=190; 20 i.v. infusions of 10 ml), other nootropics (comparator group; n=86), or a combination of both (n=122).
Report a problemFND-3441487405
07HumanObservational studyEfficacy outcome
In AIS patients, well-recovered proportions were 93.4% with combined therapy versus 43.0% with nootropics alone.
In plain wordsIn stroke patients, recovery was more frequent with Cerebrolysin plus nootropics than nootropics alone.
Peptide
Cerebrolysin
Outcome
IncreaseCombination mRS 0-2 responders
Study
n: not reported in source
Comparator
Other nootropics
Analysis
Secondary
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated
Measurements
Well-recovered patients (mRS 0-2)
93.4%
Cerebrolysin plus nootropics
Well-recovered patients (mRS 0-2)
43%
other nootropics (comparator)
p value for well-recovered patients (mRS 0-2)
< 0.001
Cerebrolysin plus nootropics versus other nootropics
Source sentences
Summary
percentage of well-recovered patients (Cerebrolysin: 81.6%; combination: 93.4%; comparator: 43.0%)
Summary
Compared with other nootropics, both Cerebrolysin and combined therapy induced significant improvements (p<0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
This non-interventional, controlled, open-label, prospective and multicenter study included 398 AIS patients (234 males) treated with Cerebrolysin (n=190; 20 i.v. infusions of 10 ml), other nootropics (comparator group; n=86), or a combination of both (n=122).
Report a problemFND-3441487407
08HumanObservational studyEfficacy outcome
In AIS patients, Cerebrolysin plus nootropics was linked to improved NIHSS change compared with nootropics alone.
In plain wordsIn stroke patients, Cerebrolysin plus nootropics was linked to better neurological scores compared with nootropics alone.
Peptide
Cerebrolysin
Outcome
DecreaseCombination NIHSS change
Study
n: not reported in source
Comparator
Other nootropics
Analysis
Secondary
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated
Measurements
p value for study-period NIHSS change
< 0.001
Cerebrolysin plus nootropics versus other nootropics
Source sentences
Summary
Compared with other nootropics, both Cerebrolysin and combined therapy induced significant improvements (p<0.001)
2 context sentences(design, population, supporting numbers)
Summary · context
neurological recovery (study- period NIHSS change)
Summary · context
This non-interventional, controlled, open-label, prospective and multicenter study included 398 AIS patients (234 males) treated with Cerebrolysin (n=190; 20 i.v. infusions of 10 ml), other nootropics (comparator group; n=86), or a combination of both (n=122).
Report a problemFND-3441487408
09HumanObservational studyEfficacy outcome
In AIS patients, good NIHSS response occurred in 92.5% with combined therapy versus 47.6% with nootropics alone.
In plain wordsIn stroke patients, neurological response was more frequent with Cerebrolysin plus nootropics than nootropics alone.
Peptide
Cerebrolysin
Outcome
IncreaseCombination good NIHSS responders
Study
n: not reported in source
Comparator
Other nootropics
Analysis
Secondary
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated
Measurements
Good NIHSS responders
92.5%
Cerebrolysin plus nootropics
Good NIHSS responders
47.6%
other nootropics (comparator)
p value for good NIHSS responders
< 0.001
Cerebrolysin plus nootropics versus other nootropics
Source sentences
Summary
proportion of good NIHSS responders (Cerebrolysin: 77.5%; combination: 92.5%; comparator: 47.6%)
Summary
Compared with other nootropics, both Cerebrolysin and combined therapy induced significant improvements (p<0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
This non-interventional, controlled, open-label, prospective and multicenter study included 398 AIS patients (234 males) treated with Cerebrolysin (n=190; 20 i.v. infusions of 10 ml), other nootropics (comparator group; n=86), or a combination of both (n=122).
Report a problemFND-3441487409
10HumanObservational studyEfficacy outcome
In AIS patients, MoCA scores were higher with Cerebrolysin plus nootropics than with nootropics alone.
In plain wordsIn stroke patients, thinking scores were higher with Cerebrolysin plus nootropics than nootropics alone.
Peptide
Cerebrolysin
Outcome
IncreaseCombination MoCA score
Study
n: not reported in source
Comparator
Other nootropics
Analysis
Secondary
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
Dose not stated
Measurements
MoCA score (mean)
23.7 points
Cerebrolysin plus nootropics
MoCA score (mean)
15.9 points
other nootropics (comparator)
p value for MoCA scores
< 0.001
Cerebrolysin plus nootropics versus other nootropics
MoCA score reported ± uncertainty (type unspecified)
4.1 points
Cerebrolysin plus nootropics at day 90
MoCA score reported ± uncertainty (type unspecified)
7.7 points
other nootropics (comparator) at day 90
Source sentences
Summary
and MoCA scores (Cerebrolysin: 23.3±4.8; combination: 23.7±4.1; comparator: 15.9±7.7).
Summary
Compared with other nootropics, both Cerebrolysin and combined therapy induced significant improvements (p<0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
This non-interventional, controlled, open-label, prospective and multicenter study included 398 AIS patients (234 males) treated with Cerebrolysin (n=190; 20 i.v. infusions of 10 ml), other nootropics (comparator group; n=86), or a combination of both (n=122).
Report a problemFND-3441487410

Studies that did not test the peptide alone4

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

11HumanNot a test of Cerebrolysin aloneObservational studyEfficacy outcome
In moderate-severe AIS, Cerebrolysin plus nootropics was linked to improved mRS outcomes compared with Cerebrolysin alone.
In plain wordsIn moderate-severe stroke, Cerebrolysin plus nootropics was linked to better disability scores compared with Cerebrolysin alone.
Peptide
Cerebrolysin
Outcome
DecreaseCombination mRS versus Cerebrolysin
Study
n: not reported in source
Comparator
Cerebrolysin alone
Analysis
Primary
Outcome group
Neuroprotection · Nervous system and cognition
Measurements
p value for mRS outcomes
< 0.01
Cerebrolysin plus nootropics versus Cerebrolysin alone in moderate-severe stroke (NIHSS>11)
Source sentences
Summary
Compared to Cerebrolysin, combined therapy improved (p11) cases only.
1 context sentence(design, population, supporting numbers)
Summary · context
This non-interventional, controlled, open-label, prospective and multicenter study included 398 AIS patients (234 males) treated with Cerebrolysin (n=190; 20 i.v. infusions of 10 ml), other nootropics (comparator group; n=86), or a combination of both (n=122).
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-3441487411
12HumanNot a test of Cerebrolysin aloneObservational studySafety outcome
In patients with acute ischemic stroke treated with Cerebrolysin, other nootropics or both, no drug-related adverse events were reported.
In plain wordsIn stroke patients treated with Cerebrolysin, other nootropics or both, the study reported no drug-related adverse events.
Peptide
Cerebrolysin
Outcome
Not applicableDrug-related adverse events
Study
n = 398
Analysis
Secondary
Outcome group
Adverse events · Whole body
Source sentences
Summary
No drug-related adverse events were reported.
1 context sentence(design, population, supporting numbers)
Summary · context
This non-interventional, controlled, open-label, prospective and multicenter study included 398 AIS patients (234 males) treated with Cerebrolysin (n=190; 20 i.v. infusions of 10 ml), other nootropics (comparator group; n=86), or a combination of both (n=122).
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-3441487414
13HumanNot a test of Cerebrolysin aloneObservational studyEfficacy outcome
In moderate-severe AIS, Cerebrolysin plus nootropics was linked to improved NIHSS change compared with Cerebrolysin alone.
In plain wordsIn moderate-severe stroke, Cerebrolysin plus nootropics was linked to better neurological scores compared with Cerebrolysin alone.
Peptide
Cerebrolysin
Outcome
DecreaseCombination NIHSS versus Cerebrolysin
Study
n: not reported in source
Comparator
Cerebrolysin alone
Analysis
Secondary
Outcome group
Neuroprotection · Nervous system and cognition
Measurements
p value for NIHSS change
< 0.01
Cerebrolysin plus nootropics versus Cerebrolysin alone in moderate-severe stroke (NIHSS>11)
Source sentences
Summary
Compared to Cerebrolysin, combined therapy improved (p11) cases only.
1 context sentence(design, population, supporting numbers)
Summary · context
This non-interventional, controlled, open-label, prospective and multicenter study included 398 AIS patients (234 males) treated with Cerebrolysin (n=190; 20 i.v. infusions of 10 ml), other nootropics (comparator group; n=86), or a combination of both (n=122).
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-3441487412
14HumanNot a test of Cerebrolysin aloneObservational studyEfficacy outcome
In moderate-severe AIS, combined therapy did not improve MoCA scores compared with Cerebrolysin alone.
In plain wordsIn moderate-severe stroke, combined therapy did not improve thinking scores compared with Cerebrolysin alone.
Peptide
Cerebrolysin
Outcome
No significant changeCombination MoCA versus Cerebrolysin
Study
n: not reported in source
Comparator
Cerebrolysin alone
Analysis
Secondary
Outcome group
Cognition and memory · Nervous system and cognition
Source sentences
Summary
Compared to Cerebrolysin, combined therapy improved (p11) cases only.
1 context sentence(design, population, supporting numbers)
Summary · context
This non-interventional, controlled, open-label, prospective and multicenter study included 398 AIS patients (234 males) treated with Cerebrolysin (n=190; 20 i.v. infusions of 10 ml), other nootropics (comparator group; n=86), or a combination of both (n=122).
In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.
Report a problemFND-3441487413

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.